Standard Biotools (LAB) Free Cash Flow (2010 - 2026)

Standard Biotools (LAB) has reported Free Cash Flow for 17 consecutive years, with -$10.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow rose 52.76% year-over-year to -$10.7 million in Q2 2026; TTM through Jun 2026 was -$82.6 million, a 21.7% increase from a year earlier, with the FY2025 full-year figure at -$82.6 million, up 45.56% from the prior year.
• Free Cash Flow was -$10.7 million for Q2 2026 at Standard Biotools, up from -$47.2 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$1.7 million in Q4 2025 and troughed at -$63.3 million in Q1 2024.
• A 5-year average of -$24.0 million and a median of -$21.2 million in 2022 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow plunged 3887.2% in 2022 and surged 90.45% in 2025, its largest moves.
• Over 5 years, Free Cash Flow stood at -$19.9 million in 2022, then rose by 29.08% to -$14.1 million in 2023, then fell by 23.35% to -$17.4 million in 2024, then surged by 90.45% to -$1.7 million in 2025, then sank by 539.56% to -$10.7 million in 2026.
• The last three Free Cash Flow figures came in at -$10.7 million (Q2 2026), -$47.2 million (Q1 2026), and -$1.7 million (Q4 2025), per Business Quant data.